Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men
Authors:
- Christina WangCWChristina Wang
- the Testosterone Gel Study GroupTGthe Testosterone Gel Study Group
- 1 June 2001
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 54 (6) , 739-750
Abstract
OBJECTIVE Androgen replacement has been reported to increase bone mineral density (BMD) in hypogonadal men. We studied the effects of 6 months of treatment with a new transdermal testosterone (T) gel preparation on bone turnover markers and BMD.DESIGN This was a prospective, randomized, multicentre, parallel clinical trial where 227 hypogonadal men, mean age 51 years (range: 19–68 years) were studied in 16 academic and research institutions in the USA. Subjects were randomized to apply 1% T gel containing 50 or 100 mg T (delivering approximately 5–10 mg T/day) or two T patches (delivering 5 mg T/day) transdermally for 90 days. At day 91, depending on the serum T concentration, the T gel dose was adjusted upward or downward to 75 mg T/day until day 180. No dose adjustment occurred in the T patch group.MEASUREMENTS Serum T, free T and oestradiol, bone turnover markers and BMD were measured on days 0, 30, 90 and 180 before and after treatment.RESULTS Application of T gel 100 mg/day resulted in serum T concentrations 1·4 and 1·9‐fold higher than in the T gel 50 mg/day and the T patch groups, respectively. Proportional increases occurred in serum oestradiol. Urine N‐telopeptide/creatinine ratio, a marker for bone resorption, decreased significantly (P = 0·0019) only in the T gel 100 mg/day group. Serum bone osteoblastic activity markers (osteocalcin, procollagen and skeletal alkaline phosphatase) increased significantly during the first 90 days of treatment without intergroup differences but declined to baseline thereafter. BMD increased significantly both in the hip (+1·1 ± 0·3%) and spine (+2·2 ± 0·5%) only in the T gel 100 mg/day group (P = 0·0001).CONCLUSIONS Transdermal testosterone gel application for 6 months decreased bone resorption markers and increased osteoblastic activity markers for a short period, which resulted in a small but significant increase in BMD. Ongoing long‐term studies should answer whether the observed increases in BMD are sustained or continue to be dependent on the dose of testosterone administered.Keywords
This publication has 44 references indexed in Scilit:
- Osteoporosis in MenThe Journal of Clinical Endocrinology & Metabolism, 1999
- Anabolic effects of parathyroid hormone on boneTrends in Endocrinology & Metabolism, 1997
- Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal MenThe Journal of Clinical Endocrinology & Metabolism, 1997
- Effect of Testosterone and Estradiol in a Man with Aromatase DeficiencyNew England Journal of Medicine, 1997
- Treatment of Isolated Hypogonadotropic Hypogonadism Effect on Bone Mineral Density and Bone TurnoverThe Journal of Clinical Endocrinology & Metabolism, 1997
- Osteoporosis in menEndocrine Reviews, 1995
- Testosterone Deficiency As a Risk Factor for Hip Fractures in Men: A Case-Control StudyThe American Journal of the Medical Sciences, 1992
- Pathogenesis of Vertebral Crush Fractures in MenAge and Ageing, 1992
- Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosisJournal of Bone and Mineral Research, 1991
- Osteoporosis in MenMedicine, 1990